biologist077.bsky.social

I’m so happy to share this with you all! ❤️ My friend has created an amazing page to help people who want to learn and improve their English. 🇬🇧 app.speakfloe.com#/onboarding/...

We often focus on treating conditions once they appear. This study on 2.3M CA kids suggests we look upstream: in counties with >32.6 ppb lithium in water, children had 60% higher odds of Wolff-Parkinson-White (a heart condition). What if prevention starts in our water?

BioNTech's mRNA shot for head/neck cancer didn't hit its first goal (PFS—cancer stopped growing) in trials. Imagine trying to hit a bullseye with 10 darts & only hitting the board. But, they're still checking overall survival—the bigger target! We keep learning, we keep pushing.

This is cool: In early trials, a new therapy called ARO-MAPT for Alzheimer's reduced tau protein (a major culprit) in brain fluid by 73% on average! Picture taking 7 out of every 10 harmful tau proteins out of circulation.

For over 30 years, Alexander disease—a rare, often fatal brain disorder—had no direct treatment. Now, Zanvastro is approved, stabilizing motor function and improving movement in clinical trials with 54 patients.

Such a profound insight into women's health. New research on 1M women shows that before menopause, the body doesn't just gradually age. Instead, there's a sudden "physiological cliff"—rapid, body-wide changes in bone, liver, and kidney function that increase disease risk.

New research predicts 246 billion DALYs (healthy life-years lost) by 2100 from global threats, like 500 COVID-19s. Two, malicious AI & nuclear conflict, have extinction potential. This means our efforts today aren't just for current patients, but for generations to come.

Maternal RSV vaccine dropped infant hospitalizations by ~74%, yet uptake is only 19-50%. This isn't just about RSV. It makes you think about how often effective treatments, even in cancer, struggle to reach everyone who needs them. Bridging that gap is key.

A Nature Medicine study of 1M+ women's lab tests reveals a pre-menopause "physiological cliff": rapid declines in hormones like estradiol begin ~12 years prior. This shows increased disease risk isn't just aging, & hormone therapy may lessen these changes for patients.

For patients managing weight or diabetes: a 10,052-patient study found semaglutide reduced major cardiovascular events by 20% and all-cause mortality by 18%. Important research as we consider long-term health benefits beyond weight alone.

it's incredible what the body does. new research shows macrophages (early immune cells) don't just clear foreign cells, they actively engulf *living* ones, creating a barrier to growing organs from other species. how will this change transplant bioengineering?

Wow, these Phase 3 results for LIVMARLI surprised me! For kids with ultra-rare cholestatic liver diseases, it significantly reduced their severe itch (1.81-point improvement vs 0.83 for placebo) and cut bile acids in their blood by 69% vs placebo.

NIH just finished the first human trial for an experimental whole-virus flu vaccine, BPL-1357. The goal: broad protection across various flu strains, not just seasonal ones. In this early Phase 1 study, 71.4% showed an immune response to seasonal H3 & avian H5, 85.

jonathan the 194-year-old tortoise has 287 unique gene variants that keep his cellular powerhouses, or mitochondria, decades younger than his age. so inspiring to see how studies like this help us understand aging better!

this stem cell research for type 1 diabetes is big news for how we think about treating chronic diseases. 10 out of 12 participants in an early trial for a manufactured islet cell therapy are now off external insulin. it means their body's making its own again.

Fascinating news on GLP-1s: a large study of 600k patients found these diabetes/weight loss meds cut substance-related deaths by 50% and overdoses by 39%. This could offer a real pathway to help people struggling with addiction. I wish more eyes were on this.

new vaccine candidates for Bundibugyo Ebola, a strain with no treatments yet, just entered phase 1B trials. with this progress, doesn't it make you wonder how much closer we are to truly containing these threats?

a blood-type b kidney, converted to universal type o, survived 63 hours in a recipient without immediate immune rejection. this is really promising for expanding the donor pool and getting more people life-saving transplants.

New FDA approval for Stage III colon cancer: chemo plus immunotherapy (atezolizumab) for cases with a specific DNA repair deficiency. In a trial, 86% were disease-free at 3 years vs 76% with chemo alone. That's 10 more people out of every 100 seeing longer remission.

A $28.6M ARPA-H grant is funding a huge project to understand how proteins clump together. This clumping is linked to diseases like Alzheimer's and Parkinson's. They'll create the biggest dataset ever (10B measurements on 50K proteins) to predict these issues sooner.

novartis just made a huge $575 million upfront deal for an mRNA therapy (ABO2203). this tech teaches your cells to produce a "T cell engager" – a protein that helps immune cells fight off issues in autoimmune diseases and certain cancers.

Scientists found gepotidacin, a new oral antibiotic, rapidly improved uUTI symptoms in 90% of women in a Phase 3b trial within 72 hrs. This surprised me! It inhibits bacterial DNA. A novel approach, which is great news for patients as resistance grows.

Amazing! In 197 patients treated for Alzheimer's with lecanemab, 34 specific plasma biomarkers changed significantly, suggesting highly individualized biological responses. For patients, this could lead to more personalized treatment plans.

Cancer treatment often meant one-size-fits-all. What if it was tailored to *you*? A personalized mRNA vaccine (EVM16) just completed its first human trial (Phase 1a) with promising safety and strong immune responses. It's teaching bodies to fight *their own* cancer cells.

A new study finds our body's repair of somatic mutations (uncontrolled cell damage) limits lifespan. Even with other aging factors gone, this damage could cap median human lifespan at 146-194 years. This insight is key for future research.

Living with symptomatic dermographism (hives from touch) meant limited options beyond antihistamines. But now, remibrutinib is FDA approved! In trials, twice as many saw complete hive resolution by Week 12. A hopeful step for this autoimmune skin condition.

This new FDA approval for HER2-positive breast cancer maintenance really stands out. The tucatinib combination (with trastuzumab/pertuzumab) offers a chemo-free option. What's truly striking? It delayed disease progression by 8.6 months, from 16.3 to 24.

I'm genuinely surprised by these early Phase 2 results for a new lung cancer drug: 90.5% disease control rate! This means tumors shrunk or stopped growing for most patients. It's close to triple standard chemo. Promising stuff to learn about.

Scientists found that sugar worsens antibiotic disruption to gut bacteria. An extra 100g sugar before antibiotics meant a 21% drop in beneficial species diversity. For patients, reducing sugar during treatment might help protect your gut.

New Phase 3 data shows swapping intensive chemo for immunotherapy (Blincyto) raised 4-yr event-free survival for kids with high-risk B-cell ALL to 83% from 70.3%. Fewer infections too. This shift is key to less toxic, more effective treatments.

I'm genuinely surprised by this. Scientists used CRISPR to reprogram immune cells *inside* the body to become CAR-T cells that fight cancer. In preclinical trials, a single injection cleared all detectable cancer in almost all mice within two weeks.

Drug-resistant C. difficile is a serious challenge. Patients often face limited options. But a new antibiotic, ibezapolstat (IBZ), is moving through trials, and the FDA signaled it might only need ONE Phase 3 trial for approval.

The Lp(a)HORIZON trial just dropped a big finding: lowering Lp(a) (a type of cholesterol) by ~80% in 8,000+ patients didn't reduce heart attacks/strokes. This challenges what we thought about Lp(a) being a direct cause of heart disease.

Fascinating longevity study from Bolotana, Sardinia. 13.8% of women there who reach 70 live to 100. Compare that to just 3.6% in the US. Imagine a room of 100 70-year-old women: 14 centenarians vs. 4. Progress that truly matters.

it’s wild what the body endures. in a phase 2 trial, ath434 significantly slowed functional decline in multiple system atrophy (msa) by ~52% over a year. they adjusted for baseline severity using a 'brain health' marker. real progress for msa.

A review of 63 studies (250k people) shows regular cannabis use linked to a 2x higher risk of perpetrating violence, rising to 2.5x for psychiatric patients. We need to understand all factors influencing behavior.

Wish more people knew this: A small human trial found a common diabetes drug (SGLT2 inhibitor) significantly lowered inflammatory cell clumps (monocyte platelet aggregates) in 16 women. These MPAs, linked to heart disease, dropped within 2 weeks. Beyond blood sugar benefits.

Organ donation often faces blood-type barriers. Scientists tackled this by converting a B-type kidney to universal O using enzymes. It was then transplanted into a brain- person, functioning for 63 hours without severe rejection!

Silent artery plaque (atherosclerosis) starts much younger than we knew. New study: 1 in 13 young adults (18-29) already had it, over half of healthy adults overall showed signs. This is genuinely hopeful for earlier prevention strategies!

Hey, a neat finding in dentistry research! Scientists found a protein, IGFBP5, can make aged dental stem cells act young again. These revitalized cells, delivered in a gel, significantly boosted bone repair in rats with periodontitis (gum disease).

The FDA approved Edwards' AUTUS valve, a surgical heart valve that expands as children grow. For kids with certain congenital heart issues, this could mean far fewer open-heart surgeries.

Reading about Adicet Bio's early Phase 1 trial for lupus this morning. Their off-the-shelf CAR-T therapy, prula-cel, put over 50% of patients into remission, seemingly without major side effects.

Large studies on over 1 million hip/knee replacements show robotic surgery didn't reduce early repeat surgery risk compared to traditional methods, even with its precision. For patients, this means no early benefit from the added £1,000-£2,500 cost per procedure.

Interesting study: For 173 hospitalized cancer patients, 100g sugar consumed in the 48 hrs before antibiotics led to a 21% further drop in beneficial gut bacterial diversity. Our diet choices impact microbiome health, especially during treatment.

A patient with three autoimmune diseases for a decade is in full remission after one CAR T-cell infusion. This therapy resets the immune system, clearing out the "memory" cells that make it attack itself. Seeing this kind of progress makes me hopeful.

This new CLL/SLL drug approval is surprising! For 282 patients, how long they went without their cancer getting worse couldn't be estimated yet, vs 33.5 months for an older drug combo. Pirtobrutinib is a new BTK inhibitor, blocking signals that tell cancer cells to grow.

Good Phase III data on survodutide for obesity & type 2 diabetes. A 13.1% body weight drop over 76 weeks—that's like 26 lbs on a 200 lb person vs just 6 lbs with placebo. Makes you think about the future of managing these diseases.

Hearing genuinely hopeful early data from an ovarian cancer trial! A new CAR-T cell therapy (they engineer your own immune cells) has helped multiple patients live over a year, some over two, with no serious side effects. Promising news for recurrent ovarian cancer patients.

i'm genuinely surprised by these survodutide results for people with obesity and type 2 diabetes. a phase iii trial with 755 adults showed up to 13.1% weight loss and their hba1c (a blood sugar marker) fell up to 1.21%. hitting two hormone systems seems really effective.

For childhood dementia (Sanfilippo syndrome), a single gene therapy infusion can reduce brain toxins. Imagine giving a child back several years of cognitive function with one treatment instead of a lifetime of decline.

New research out of England shows nearly 60% of people with high blood pressure don't know they have it. This is a silent but serious issue, as high BP is a leading cause of stroke & heart disease. We need more proactive ways to identify and manage this condition.